Connect with us

Hi, what are you looking for?

Monday, Feb 26, 2024
Mugglehead Magazine
Alternative investment news based in Vancouver, B.C.


Tilray to provide cannabis for Spanish clinical study on severe brain cancer

Glioblastoma is an aggressive form of brain cancer that can potentially kill an individual within six months

Tilray to provide cannabis for Spanish clinical study on severe brain cancer
Glioblastoma. MRI brain scan image via the Washington University School of Medicine in St. Louis

Tilray Medical, a subsidiary of Tilray Brands, Inc. (Nasdaq: TLRY) (TSX: TLRY), will be supplying cannabis extract for a new clinical trial in Spain aimed at combatting a severe form of brain cancer.

On Monday, the major cannabis company announced its sponsorship of the upcoming study on glioblastoma. The clinical trial will be conducted at the University Hospital 12 de Octubre in Madrid by scientists from the Spanish Neuro-Oncology Research Group (GEINO) and the Complutense University of Madrid.    

The trial will recruit 30 newly diagnosed patients from eight specialized neuro-oncology sites in Spain. It will examine the impact of Tilray Medical’s THC and CBD extract T10:C10 in combination with the orally administered drug temozolomide and radiation therapy.

“This groundbreaking trial is more than an opportunity for Tilray to engage in medical research; it’s a beacon of hope for patients suffering from glioblastoma,” said Tilray’s Chief Strategy Officer Denise Faltischek.

The study will be led by GEINO’s neurologist Dr. Juan Manuel Sepúlveda Sánchez and it is being funded by the charity Medical Cannabis Bike Tour Foundation (MCBTF), which is based in Amsterdam.

Read more: A Little Bud opens first cannabis store in Whistler

Read more: Kitchener RCMP uncover major drug haul and weapons cache during cannabis plant investigation

Cannabis and its derivatives have long been known to be beneficial for cancer patients

Tilray says this study is the culmination of a 10-year civil society collaboration between the scientific sector and the medical cannabis community.

“Biological evidence has been accumulating for more than 15 years that cannabinoids have anti-tumor activity in the most aggressive brain tumors, glioblastomas,” said Sánchez.

“However, no clinical trials have been conducted to prove this hypothesis in patients. With this clinical trial, we can finally study the effect of cannabinoids on tumors that have not received active treatment,” he added.

The MCBTF began raising funds to support researchers at the Complutense University of Madrid a decade ago who were studying the potential of cannabinoids for the treatment of cancer cells and glioblastoma. 

“The fact that the Medical Cannabis Bike Tour can now independently fund a clinical trial in the name of science is amazing, thanks to the sponsors and riders who made it happen. We hope this trial will reflect the hope illuminated by the scientific research for the participants involved,” said the charity’s Founder Luc Krol.

In May this year, Tilray Medical supported Italy’s cancer and patient care conference ONCOWELLNESS, which was accredited by the country’s Ministry of Health.

A study from University of Colorado Boulder in April this year found that cannabis can significantly improve sleep, relieve pain and enhance mental clarity in cancer patients.

Recent surveys have found that between 22-40 per cent of cancer patients will use cannabis for purposes such as managing pain and anxiety, according to an article last year in the Journal of Clinical Oncology.

Mugglehead reached out for information about when the trial was expected to begin and will update this article accordingly.

Tilray shares have steadily dropped by over 40 per cent in the past year and are currently worth $2.77 on the Toronto Stock Exchange.


Follow Mugglehead on X

Follow Rowan Dunne on X

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like


The country's lawmakers voted 407 to 226 in favour of the new legislation


The group was established last year and formally announced by the government on Friday


Retailers are now permitted to promote consumption locations as well


Its subsidiary Valiant will be distribute merchandise for the Manitoba Liquor and Lotteries Corporation